Cellia Science, Inc.

Cellia Science, Inc. is a for-profit corporate entity based in Fayetteville, Arkansas, specializing in advanced medical diagnostic technologies with a focus on innovative point-of-care diagnostic instruments. The company leverages deep ultraviolet (UV) microscopy and machine learning techniques to develop cutting-edge diagnostic tools that enable rapid, non-destructive medical assessments across various clinical domains. Registered in SAM.gov since March 2022, Cellia Science has demonstrated a strategic approach to developing transformative medical technologies that address critical diagnostic challenges in healthcare.

The company has secured multiple federal grant awards from agencies including the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the National Institute of Allergy and Infectious Diseases, and the National Heart Lung and Blood Institute. These grants, totaling approximately $1.4 million, support the development of sophisticated point-of-care diagnostic technologies, such as a rapid diagnostic tool for Spontaneous Bacterial Peritonitis (SBP), a bone marrow aspiration sample adequacy assessment instrument, and a microfluidic cartridge for hematology analysis. Each project involves developing advanced imaging and machine learning techniques to improve medical diagnostics, with specific focuses on creating faster, more accurate diagnostic methods for complex medical conditions. The grants demonstrate Cellia Science's expertise in creating innovative medical technologies that can potentially revolutionize diagnostic processes by providing real-time, accurate assessments in clinical settings.